Fairfax strategically over-reserves in its insurance businesses. This defers income, reduces current tax liabilities, and creates a conservative balance sheet where future equity is embedded in the reserves, which can be released later, even against auditor pressure.

Fairfax employs a clever M&A strategy called the "cannibal buy-up." When an asset is too large to acquire outright, they partner with another firm. Later, when financially stronger, they use their capital to buy out the partner's stake, allowing them to gain 100% control of a valuable asset over time.

Fairfax India, trading around $18, has a realizable intrinsic value of $35-40+. This massive discount persists because its monopoly-like assets are carried at understated values, and its shareholder base lacks investors willing to pay a premium to its stated book value.

In private markets, there's a perverse incentive for both private equity owners and private credit lenders to avoid marking down asset values. This "mark to make-believe" system keeps valuations artificially high, hiding underlying financial stress and delaying the recognition of losses.

Fairfax follows a clear capital allocation framework. They prioritize open market buybacks when the stock is below 1.5 times price-to-book. Above that multiple, they shift capital towards closing out their Total Return Swaps, providing a predictable approach for investors.

Fairfax executed a brilliant capital allocation move by selling a 10% stake in its subsidiary, Odyssey, to pension funds for 1.7 times its book value. They then used the billion-dollar proceeds to buy back their own undervalued parent company stock, which was trading at a discount of 0.9x book value.

Fairfax maintains a balance sheet with roughly $75 billion in investments against $25 billion in equity. This leverage is primarily funded by low-cost insurance float and some debt, creating a powerful engine for returns that the speakers argue is a "better mousetrap than Berkshire."

Private credit assets lack the price discovery of public markets. Their value is typically assessed quarterly by third-party services, meaning the "marks" on a fund's books can lag significantly behind reality. This creates a hidden risk: in a downturn, the actual sale price could be far below the stated value.

Despite compounding book value at ~20% annually, Fairfax's stock multiple has stagnated. The speakers argue this is because Canadian institutional managers, who are key investors, are selling due to slowing top-line premium growth, ignoring the underlying value creation.